- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06078514
Sexual Function and Quality of Life After LEEP: A Prospective Multi-Center Study (SEQUEL)
The goal of this prospective study is to investigate the sexual function and quality of life of women undergoing loop electrosurgical excision procedure (LEEP) due to HPV-related cervical lesion.
The main question it aims to answer are:
- Whether LEEP affects the sexual function of women in comparison to untreated women, and
- Whether LEEP affects the health-related quality of life of women in comparison to untreated women
Participants are asked to complete web based an international validated self-report questionnaire on sexual function issues, the Female Sexual Function Index (FSFI), and a validated quality of life -questionnaire 15D at the time of first colposcopy appointment and six and 24 months, 3 years and 5 years after index visit (LEEP or first colposcopy in control group). Relevant additional background information is also collected via questionnaire and from patient files.
Researchers will compare women with LEEP and those with only colposcopy visits to see any differences between self-reported sexual function (FSFI scores) or health-related quality of life (15D scores) both short and long-term.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
We plan to recruit minimum of 1000 women referred to colposcopy in Tampere University Hospital, Helsinki University Hospital, Kuopio University Hospital, Oulu University Hospital, North Karelia Central Hospital and Hyvinkää Hospital to our prospective multi-center study. Recruitment is done at gynecology outpatient clinics of the participating units at the first colposcopy visit, where the doctor performing the colposcopy informs the eligible women about the study, gives them the patient information letter, and asks them to participate and, if they agree, to fill in the informed consent. We aim to recruit 500 women undergoing LEEP (intervention arm) and at least 500 undergoing only colposcopy (control arm).
Pirkanmaa Hospital District Ethical Review Board has approved the study design and local scientific committees in each university hospital area applied for permission to launch the study.
In each participating unit, eligible women will be given a written patient information sheet on the study and asked to participate. From women willing to participate, a written informed consent will be collected and stored in locked cabinet in participating unit. These documents will be accessed only by study members.
Participants are contacted due to the study 5 times: at the time of recruitment, 6 months after the index visit (either first colposcopy or LEEP visit) and 24 months, 3 years and 5 years after the index visit. Each time they are asked to fill in the same questionnaires, sent by mail and available also web based. No additional visits are needed, nor any extra samples taken.
The study data is collected using REDCap system designed for safe patient data management. Access to the system is strictly restricted to the research team members, that are committed to handle the data according to good clinical practice.
At the end of the study, the digital data is to be stored at Pirkanmaa Hospital Disctrict official research files, where individual patient data will be available only for identified study members. In the analysis the data will be used pseudonymized. Informed consents will be stored in participating research units.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Laura Kotaniemi-Talonen, PhD
- Phone Number: +358 3 311 66008
- Email: laura.kotaniemi-talonen@pirha.fi
Study Locations
-
-
-
Tampere, Finland
- Tampere University Hospital
-
Contact:
- Karolina Louvanto, Prof.
- Email: karolina.louvanto@tuni.fi
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age 18 to 70 years
- First colposcopy visit (in 24 months, if previous colposcopies)
- Referral for cytological changes or repeated HPV positivity
- No previous LEEP or other operations affecting the length of cervix
- Not pregnant at the time of colposcopy/LEEP
- Sexually active
- Capable of understanding the study protocol - informed consent given
- Fluent in Finnish
Exclusion Criteria:
- Age less than 18 or more than 70 years
- Previous colposcopy within 24 months
- Referral for other reason, e.g. vulvar lesion
- Previous LEEP or other operation affecting the length of cervix
- Pregnant at the time of colposcopy/LEEP
- Sexually inactive
- Unable to understand the study protocol - no informed consent
- Difficulties in understanding Finnish
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Loop electrosurgical excision procedure (LEEP)
Women directed to colposcopy examination due to cytological abnormality or repeated HPV-positivity and undergone a LEEP procedure due to HPV-related cervical lesion
|
The affected area of cervix is excised under local anesthesia using a small thin electrically charged hardwire loop for simultaneous cutting and electrocoagulation.
Other Names:
|
Colposcopy only
Women directed to colposcopy examination due to cytological abnormality or repeated HPV-positivity with no indication to LEEP
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Self-reported sexual function measured by Female Sexual Function Index (FSFI)
Time Frame: From 6 months up to 5 years since the initiation of the study
|
Female Sexual Function Index (FSFI) is a 19-item self-report measure that provides scores on overall levels of sexual function as well as the primary components of sexual function in women, including sexual desire, arousal, orgasm, pain, and satisfaction.
For scoring it uses a 5-point Likert scale ranging from 1-5 with higher scores indicating greater levels of sexual functioning on the respective item.
Total that scores of ≤26.55 are considered to present clinically relevant sexual dysfunction (specificity = 0.733; sensitivity = 0.889).
|
From 6 months up to 5 years since the initiation of the study
|
Self-reported health-related quality of life measured by 15D
Time Frame: From 6 months up to 5 years since the initiation of the study
|
15D is a generic, comprehensive, 15-dimensional, standardized, self-administered measure of health-related quality of life (HRQoL).
It includes the following 15 dimensions: breathing, mental function, speech (communication), vision, mobility, usual activities, vitality, hearing, eating, elimination, sleeping, distress, discomfort and symptoms, sexual activity, and depression.
The maximum score is 1 (no problems on any dimension) and the minimum score is 0. A change of 0.02-0.03
has been observed to be such that people can feel the difference.
|
From 6 months up to 5 years since the initiation of the study
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Laura Kotaniemi-Talonen, PhD, Tampere University Hospital
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- R22017
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cervical Dysplasia
-
University of Mississippi Medical CenterNot yet recruitingCervical Dysplasia, Uterine | Vaginal Dysplasia | Vulvar Dysplasia
-
National Institute of Allergy and Infectious Diseases...Hoffmann-La RocheCompletedHIV Infections | Cervix, DysplasiaUnited States, Puerto Rico
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Terminated
-
Sunnybrook Health Sciences CentreCompleted
-
Ruhr University of BochumCompletedUterine Cervical DysplasiaGermany
-
Indiana UniversityRecruitingHIV Infections | HIV/AIDS | Cervical DysplasiaKenya, United States, Uganda
-
University of CopenhagenDanish Cancer SocietyUnknown
-
University of TennesseeIntegra LifeSciences CorporationCompletedCervical DysplasiaUnited States
-
University of AarhusNot yet recruitingCervical Cancer
-
NHS Greater Glasgow and ClydeUnknownCervical Carcinoma | Cervical Dysplasia
Clinical Trials on Loop electrosurgical excision procedure (LEEP)
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedCervical CancerUnited States, Canada
-
Ontario Clinical Oncology Group (OCOG)Canadian Institutes of Health Research (CIHR)CompletedCervical Intraepithelial NeoplasiaCanada, Brazil
-
AIDS Clinical Trials GroupNational Institute of Allergy and Infectious Diseases (NIAID)CompletedHIV-1 InfectionPeru, Malawi, South Africa, Zimbabwe, Haiti, Botswana, India
-
Instituto Nacional de Saúde, MozambiqueM.D. Anderson Cancer CenterNot yet recruitingHIV Infections | HPV Infection | CIN 2/3Mozambique
-
Ruhr University of BochumRecruiting
-
Oswaldo Cruz FoundationCompletedCervical Intraepithelial NeoplasiaBrazil
-
University of WashingtonUniversity of Nairobi; International Agency for Research on CancerCompletedCervical Intraepithelial NeoplasiaKenya
-
Centre Hospitalier Universitaire, AmiensCompletedPregnancy Complications
-
Oswaldo Cruz FoundationCompletedCervical Intraepithelial NeoplasiaBrazil
-
National Cancer Institute (NCI)TerminatedCervical Cancer | Cervical Intraepithelial Neoplasia Grade 2 | Cervical Intraepithelial Neoplasia Grade 3United States